atai Life Sciences Shares Upcoming Investor Conference Details
atai Life Sciences Announces Participation in Investor Conferences
atai Life Sciences (NASDAQ: ATAI), a pioneering company in the biopharmaceutical field, is dedicated to revolutionizing mental health treatment outcomes. Recently, the management team announced participation in several noteworthy investor conferences this June, intended to share insights about their innovative therapies and vision.
Upcoming Conferences Scheduled
Jefferies Global Healthcare Conference
This esteemed conference will feature a fireside chat format on Thursday, June 5, at 9:55 A.M. EDT. While the meeting is set to take place in New York, those interested can expect significant insights from the discussion.
H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Additionally, atai Life Sciences will participate in a pre-recorded fireside chat during this hybrid conference on Tuesday, June 17, at 7:00 A.M. EDT. This virtual event provides an excellent opportunity for the company to share its latest developments with a broader audience.
Access to Webcasts
Both conferences will feature webcasts, allowing attendees and interested parties to engage in the discussions. For those unable to attend live, recordings will be accessible afterward on the investor section of the atai Life Sciences website.
About atai Life Sciences
atai Life Sciences is a clinical-stage biopharmaceutical company committed to developing impactful mental health treatments. Their innovative pipeline includes psychedelic-based therapies, such as VLS-01 (buccal film DMT) designed for treatment-resistant depression, and EMP-01 (oral R-MDMA), aimed at treating social anxiety disorder. Both therapies are currently in Phase 2 clinical development.
Moreover, atai is conducting an exciting drug discovery program focusing on identifying new, non-hallucinogenic 5-HT2AR agonists for addressing treatment-resistant depression. By tackling the multifaceted nature of mental health issues, atai aims to offer scalable psychiatric therapies that integrate smoothly into existing healthcare systems.
To stay updated on their groundbreaking work, visit www.atai.com or connect on LinkedIn.
Contact Information
Investor Contact:
Email: IR@atai.com
Media Contact:
PR@atai.com
Frequently Asked Questions
What is atai Life Sciences focused on?
atai Life Sciences is focused on developing innovative mental health treatments using psychedelic-based therapies.
Which conferences is atai attending this June?
atai will attend the Jefferies Global Healthcare Conference and the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference.
How can I access the webcasts of the conferences?
The webcasts are available on the investor section of the atai Life Sciences website, with replays accessible after the live events.
What therapies is atai developing?
atai is developing VLS-01 for treatment-resistant depression and EMP-01 for social anxiety disorder, both in Phase 2 clinical development.
Where can I find more information about atai Life Sciences?
More information can be found on their official website, www.atai.com.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.